226950.KQ Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 03:16):

OliX Pharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases...

Stats
Dzisiejszy wolumen	6 610.00
Średni wolumen	108 209
Kapitalizacja rynkowa	254.01B
EPS	KRW0 ( 2024-03-15 )
Następna data zysków	( KRW0 ) 2024-05-09
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW23.20 (0.15%)

Wolumen Korelacja

Długi: -0.14 (neutral)

Krótki: -0.02 (neutral)

Signal:(44.97) Neutral

OliX Pharmaceuticals,Inc Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

OliX Pharmaceuticals,Inc Korelacja - Waluta/Towar

0.44
( neutral )

0.23
( neutral )

0.44
( neutral )

0.45
( neutral )

0.13
( neutral )

0.06
( neutral )

OliX Pharmaceuticals,Inc Finanse

Annual	2023
Przychody:	KRW17.06B
Zysk brutto:	KRW14.42B (84.52 %)
EPS:	KRW-1 323.81

FY	2023
Przychody:	KRW17.06B
Zysk brutto:	KRW14.42B (84.52 %)
EPS:	KRW-1 323.81

FY	2022
Przychody:	KRW9.32B
Zysk brutto:	KRW7.35B (78.83 %)
EPS:	KRW-1 422.69

Financial Reports:

No articles found.

OliX Pharmaceuticals,Inc

OliX Pharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101 for skin scar; OLX102 for skin whitening; OLX103, an atopic dermatitis product; OLX104 for hair loss; OLX105, an anti-wrinkle product; and OLX106 for diabetic foot ulcer. Its products pipeline also comprise OLX301 for age-related macular degeneration retinal fibrosis; OLX304 for retinitis pigmentosa; OLX201 for lung fibrosis; OLX202 for asthma; OLX203 for influenza; OLX401 for neuropathic pain; OLX701 for liver fibrosis; and OLX701 for cancer immunotherapy. The company has a collaboration agreement with Théa to develop SiRNA therapeutics for ophthalmic diseases; and a research collaboration with PCI Biotech Holding ASA. OliX Pharmaceuticals, Inc. was founded in 2010 and is based in Suwon, South Korea.